Product Name
CYP4V2, siRNA
Full Product Name
CYP4V2 siRNA (Human)
Product Synonym Names
Cytochrome P450 4V2
Product Gene Name
CYP4V2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q6ZWL3
Specificity
CYP4V2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CYP4V2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CYP4V2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CYP4V2 sirna
siRNA to inhibit CYP4V2 expression using RNA interference
Applications Tested/Suitable for CYP4V2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CYP4V2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_997235.3
[Other Products]
NCBI GenBank Nucleotide #
NM_207352.3
[Other Products]
UniProt Primary Accession #
Q6ZWL3
[Other Products]
UniProt Secondary Accession #
Q6ZTM4; B7U6W2[Other Products]
UniProt Related Accession #
Q6ZWL3[Other Products]
Molecular Weight
58,166 Da
NCBI Official Full Name
cytochrome P450 4V2
NCBI Official Synonym Full Names
cytochrome P450, family 4, subfamily V, polypeptide 2
NCBI Official Symbol
CYP4V2 [Similar Products]
NCBI Official Synonym Symbols
BCD; CYP4AH1
[Similar Products]
NCBI Protein Information
cytochrome P450 4V2
UniProt Protein Name
Cytochrome P450 4V2
UniProt Synonym Protein Names
Docosahexaenoic acid omega-hydroxylase CYP4V2
Protein Family
Cytochrome
UniProt Gene Name
CYP4V2 [Similar Products]
UniProt Entry Name
CP4V2_HUMAN
NCBI Summary for CYP4V2
This gene encodes a member of the cytochrome P450 hemethiolate protein superfamily which are involved in oxidizing various substrates in the metabolic pathway. It is implicated in the metabolism of fatty acid precursors into n-3 polyunsaturated fatty acids. Mutations in this gene result in Bietti crystalline corneoretinal dystrophy. [provided by RefSeq, Jul 2008]
UniProt Comments for CYP4V2
CYP4V2: Catalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. The substrate specificity is higher for myristate > laurate > palmitate (C14>C16>C12). May have a role in fatty acid and steroid metabolism in the eye. Defects in CYP4V2 are a cause of Bietti crystalline corneoretinal dystrophy (BCD). BCD is an autosomal recessive retinal dystrophy characterized by multiple glistening intraretinal crystals scattered over the fundus, a characteristic degeneration of the retina, and sclerosis of the choroidal vessels, ultimately resulting in progressive night blindness and constriction of the visual field. Most cases have similar crystals at the corneoscleral limbus. Clinically, BCD is progressive. Patients develop decreased vision, nyctalopia, and paracentral scotomata between the 2nd and 4th decade of life. Later, patients develop peripheral visual field loss and marked visual impairment, usually progressing to legal blindness by the 5th or 6th decade of life. Belongs to the cytochrome P450 family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; EC 1.14.13.199; Oxidoreductase
Chromosomal Location of Human Ortholog: 4q35.2
Cellular Component: endoplasmic reticulum membrane; integral to membrane
Molecular Function: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen; iron ion binding; heme binding; monooxygenase activity
Biological Process: visual perception; response to stimulus; fatty acid omega-oxidation
Disease: Bietti Crystalline Corneoretinal Dystrophy
Research Articles on CYP4V2
1. A (p.F73L) mutation may be a recurrent mutation in Chinese patients with Bietti crystalline dystrophy (BCD).">cytochrome P450 family 4 subfamily V polypeptide 2 (CYP4V2) c.219T>A (p.F73L) mutation may be a recurrent mutation in Chinese patients with Bietti crystalline dystrophy (BCD).
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
